Pasithea Therapeutics (KTTA) Profit After Tax (2021 - 2026)

Pasithea Therapeutics' Profit After Tax history runs 6 years deep, the most recent figure standing at -$2.9 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 19.47% year-over-year to -$2.9 million; the TTM figure through Mar 2026 stood at -$19.7 million (down 45.03% YoY), while the FY2025 annual figure was -$20.4 million, down 46.91% from the prior year.
• Profit After Tax came in at -$2.9 million for Q1 2026 at Pasithea Therapeutics, up from -$10.1 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$1.6 million in Q1 2022 to a low of -$10.1 million in Q4 2025.
• A 5-year average of -$3.8 million and a median of -$3.6 million in 2025 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax slumped 561.66% in 2022 and jumped 30.83% in 2024, its largest moves.
• Pasithea Therapeutics' Profit After Tax stood at -$2.9 million in 2022, then plunged by 57.93% to -$4.6 million in 2023, then surged by 30.83% to -$3.2 million in 2024, then sank by 218.19% to -$10.1 million in 2025, then soared by 71.62% to -$2.9 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$2.9 million, -$10.1 million, and -$3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison